Selcia Appoints Simon Saxby as CEO and Andreas Rummelt to its Board
News Feb 24, 2011
Selcia, has appointed Simon Saxby as its Chief Executive Officer (CEO). He will assume his position in April and takes over from Dr Hans Fliri who retains his role as Chairman of the Board. Selcia also announce the appointment of Dr Andreas Rummelt as a Non-Executive Director.
Chairman Dr Hans Fliri said, "I am very pleased to announce our two high profile appointments. Simon Saxby, until recently CEO of Cobra Biomanufacturing PLC and who joined Selcia’s Board last year, brings successful leadership and executive management experience to the role of Selcia’s CEO. Andreas Rummelt, formerly CEO of Sandoz and a member of the Novartis Executive Committee was recently appointed as Partner and CEO of the Swiss management consulting firm InterPharmaLink AG. Andreas is recognized as a global expert in drug development and will further enhance the strategic strength of Selcia’s Board. Both Simon and Andreas have a wealth of international experience and connections in the pharmaceutical industry and this expertise will be highly significant as Selcia plans its growth and expansion in the future".
Commenting on his appointment as CEO, Simon Saxby said, “With the increasing trend of outsourcing in the pharmaceutical and biotech sectors, this is an exciting time to be joining Selcia. I welcome the opportunity to work with Selcia’s management team and scientists as we expand the business through strategic partnerships built around the provision of high value services to our important and valued customers”.
On joining the Board, Dr Andreas Rummelt said, “Selcia has a track record of providing excellent custom radiolabelling and drug discovery services. I am pleased to bring my drug development, contract manufacturing and partnering expertise to support Selcia’s management team. I look forward to working with the Board to help define Selcia’s strategy for further expansion in the rapidly changing life sciences sector”.
Researchers Develop Novel ‘One-pot’ Approach to Conjugated Tetraenes SynthesisNews
TUAT researchers have achieved the new synthetic route of conjugated tetraenes from inexpensive and easily available 1,3-butadiene and substituted acetylenes by a one-pot approach under mild conditions. Conjugated tetraenes are important key substructures in biologically active natural products such as vitamins, and anti-mycotic drugs.READ MORE
Cancer Fighting Compound Activated by Substance Found in Stinging NettlesNews
Researchers have developed a new line of attack against cancer: an organic-osmium compound, which is triggered using a non-toxic dose of sodium formate, a natural product found in many organisms, including nettles and ants.READ MORE